How the CEO of Mark Cuban Cost Plus Drug Co. aims to upend the PBM model
W hen Alexander Oshmyansky, MD, PhD, pitched the idea of a not-for-profit drug company that would undercut drugmakers’ excessively priced pharmaceuticals, he was soundly rejected by potential backers, attracting no outside money. But on the advice to try to create a for-profit company instead, and with the later backing of Mark Cuban, things started to happen.…
Revenue Cycle Insights newsletter: Medicare outpatient payment bump less than first appears
On the surface, CMS is granting Medicare outpatient care a 3.8% payment increase, but a variety of negative adjustments that will vary by provider are going to cut into the net gain. Senior Editor Nick Hut breaks it all down. Also, Vanderbilt Health is reaping gains from its earlier adoption of automation technology in revenue…
Staff, patients, benchmarks have the attention of rev cycle leaders
5 takeaways from HFMA’s Revenue Cycle Conference
Revenue Cycle Insights: March 2022
Workforce shortages are affecting revenue cycle functions, and you can learn how executives from Spectrum Health and Stanford Health Care are limiting the damage in the lead story of March's Revenue Cycle Insights.
Annual Conference Day 2: Culture of healthcare slows needed change, says keynoter Robert Pearl, MD
Recognizing the strengths and weaknesses of healthcare’s culture is key to implementing needed industry changes, according to Robert Pearl, MD, former CEO of Permanente Medical Group.
Hospital CFOs concerned about service lines; some embrace coming disruption
A survey conducted by HFMA for the Healthcare 2030 special series shows CFOs as expecting big changes to the hospital and health system operating model.